Many of these novel therapeutic agents are already being tested in clinical trials and they may 1 day reshape the landscape of SLE treatment
We have to consider that stimulating a given nucleus might not only result in a specific outcome because of its circuit connectivity, but also because each nucleus could have a very different composition of glutamatergic, GABAergic, and glycinergic neurons
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal toxicology shows wide therapeutic window Injection-site reactions reported anecdotally Known interactions Anticoagulants (theoretical, due to angiogenic activity unstudied) Contraindications Active malignancy (theoretical, due to angiogenic mechanism) Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A
The copper part isnt a footnote
As the pace at which antibiotic discovery lags behind resistance, not too many treatment options will remain effective in the coming years, plunging the world into a scenario that looks like a post-antibiotic era [27]
How this plays out in practice can vary from person to person, and a qualified healthcare provider can help determine what makes sense for your individual situation
